Abstract
IntroductionMigraine affects 8% of children, and may require pharmacological therapy to control symptoms. Current acute treatments include (5-Hydroxytryptamine Receptor 1 (5-HT1) receptor agonists, although the only licensed medication for paediatric...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Hospital Pharmacy: Science and Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
